i2O Therapeutics is a biotechnology company developing safe and effective oral formulations of therapies traditionally limited to injections. Using an innovative ionic liquid technology, this platform leverages the benefits of protecting the drug cargo while also transiently enhancing permeation across the epithelial lining when administered orally. i2O is focused on creating the next generation of oral peptide and protein-based therapies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/09/20 | $4,000,000 | Seed |
JDRF T1D Fund Sanofi Ventures  | undisclosed |
